Dimerix (ASX:DXB) has announced that 167 patients have now been recruited into the feasibility/Phase 3 ACE2 renin-angiotensin system (RAS) modulation study domain in patients with COVID-19 pneumonia that incorporates DMX-200.
The company said that of those 167 subjects enrolled across 43 clinical sites, 106 have been recruited in sites across the UK, 60 in the Netherlands and 1 in Italy.
DMX-200 has regulatory approval in both the UK and the Netherlands and is available at sites for administration to patients randomised to the DMX-200 treatment arm.
In the REMAP-CAP approved ACE2 RAS study domain, participants who meet platform entry criteria will be randomised to receive one RAS blockade treatment arm or a control:
- Angiotensin receptor blocker (ARB) in combination with DMX-200;
- ARB;
- Angiotensin-converting enzyme (ACE) inhibitor; and
- No RAS inhibitor (no placebo).
DMX-200 is now part of two different investigator-led Phase 3 studies in COVID-19 patients with respiratory complications. For one of these studies, Dimerix was awarded $1 million from MTPConnect’s Biomedical Translation Bridge (BTB) program provided by the federal government’s Medical Research Future Fund, with support from UniQuest.
Dimerix also said it continues to progress the Phase 3 program in focal segmental glomerulosclerosis. This is a rare kidney disorder without an approved pharmacologic treatment that often leads to end-stage kidney failure.